Sanofi has pulled the plug on its experimental Clostridium difficile vaccine after an interim analysis of a late-stage trial concluded that key targets were unlikely to be met.
The Phase III Cdiffense trial is designed to test the efficacy and safety of a candidate toxoid vaccine in a subpopulation at risk of Clostridium difficile infection.
Sanofi said on the back of the Independent Data Monitoring Committee (IDMC)’s analysis it has decided to discontinue clinical development of the vaccine, “to focus on six key vaccine projects currently in development.”
Data from all vaccinated volunteers in the trial will continue to be analysed for more information and shared with the scientific community, the French drugmaker added.
